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ABSTRACT
In a prospective survey conducted between May 1998 and September 2001, the prevalence of carriage of
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and gen-
tamicin-resistant Gram-negative bacilli (GGNB) was determined in 1167 patients repatriated from
foreign hospitals to The Netherlands. Swab specimens, demographic data and clinical data were
obtained during transfer of the patients from the foreign hospitals. The total prevalence of carriage of
resistant microorganisms was 18.2%. MRSA was carried by 2.7% of all patients, and by 4.7% of the
patients repatriated to a Dutch hospital. Antimicrobial treatment (adjusted odds ratio (OR) 3.4; 95%
confidence interval (CI) 1.2–9.7), length of stay in a foreign hospital of > 14 days (adjusted OR 5.4; 95%
CI 2.3–12) and artificial ventilation (adjusted OR 8.5; 95% CI 1.8–41) were risk factors for carriage of
MRSA. VRE and GGNB were isolated from 2.7% and 14.1% of the patients, respectively. Transfer from
Asia, and southern, southeastern and eastern Europe, were risk factors for carriage of GGNB. These
carriage rates were high compared to those found in patients in Dutch hospitals, where the rates are
< 1% for MRSA, 2% for VRE, and 4.5% for GGNB. The highest risk of acquisition of GGNB was
associated with the country from where the patient was repatriated, rather than with the antimicrobial
treatment received by the individual patient in the foreign hospital.
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INTRODUCTION
The Netherlands is a country with a very low
antimicrobial resistance rate [1–3]. The preval-
ence of methicillin-resistant Staphylococcus aureus
(MRSA) is still < 1%, both in the community and
among hospitalised patients. Although the pre-
valence of carriage of vancomycin-resistant enter-
ococci (VRE) in the gastrointestinal tract is 2% in
hospitals and the community, outbreaks of VRE in
Dutch hospitals are very rare [1,4]. Less is known
about resistance among Gram-negative bacilli, but
the general impression is that resistance rates for
these microorganisms are also lower than in many
other countries [5].
It is generally assumed that the judicious use
of antimicrobial agents in The Netherlands [6] is
a key factor in maintaining these low resistance
levels. In addition, The Netherlands has adopted
a national policy towards the control of MRSA
[7]. As part of this policy, patients transferred to
Dutch hospitals from hospitals in other countries
are admitted to single rooms and held in
quarantine until the results of screening for
colonisation with MRSA are negative. This
policy was introduced after experiences in the
early 1980s, when the first hospital outbreaks of
MRSA occurred after introduction of these
strains by patients who came from foreign
hospitals [8].
The present study evaluated the frequency of
introduction of MRSA into The Netherlands by
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patients who had received treatment in foreign
hospitals. The prevalence of carriage of VRE
and of gentamicin-resistant Gram-negative bacilli
(GGNB) was also determined. The study was a
prevalence survey for carriage at the moment of
repatriation. As such, the study provides data that
mirror the risk of acquisition of resistant strains in
hospitals worldwide.
MATERIALS AND METHODS
Patients
Consecutive patients who had stayed in a foreign hospital
for at least 24 h and who were repatriated to The Nether-
lands between May 1998 and September 2001 by one of
the following organisations were included: ANWB, SOS,
EuroCross International, Broeder de Vries, Internationale
Ambulance IA, Omnicare and Verenigd Ziekenvervoer
Amsterdam. These repatriation services account for > 90%
of escorted Dutch repatriating ambulances (G. J. Kruithof,
personal communication). Patients giving informed consent
were entered into the study during the repatriation journey.
Ambulance staff filled out a case record form and took swab
specimens for culture from nares, throat and anus. Case
record forms and specimens were sent to our institute by
mail. Case record form information was based on the
patient’s hospital medical record and information recorded
during repatriation. It comprised demographic data (year of
birth, gender), country from which the patient was repatri-
ated, and place of repatriation (Dutch hospital or the
patient’s home). In addition, disease and intervention data
were collected.
Reference data for carriage of MRSA, VRE and GGNB in
The Netherlands
Data from earlier surveillance studies were used as a reference
for the MRSA carriage rate [1,9]. The continuous surveillance
performed by the National Institute of Public Health and
Environmental Protection (Bilthoven, The Netherlands) has
shown a steady increase in the isolation rate of MRSA in The
Netherlands over the years, but the total carriage rate of MRSA
is still < 1%.
Data on the faecal carriage of VRE in The Netherlands were
available [1,4] for use as a reference. The present study used
the same methods for carriage detection and susceptibility
testing, and the same criteria for definition of resistance, as in
previous studies.
As no reference data on the carriage of GGNB in Dutch
hospitals were available, a small prevalence study was
conducted. Anal swab specimens were obtained for culture
from 200 adult patients who had been in a Dutch hospital for
between 3 and 13 days. These patients were consecutive
patients admitted to either internal medicine, cardiology,
pulmonary disease, surgery or intensive care units in any of
the following hospitals: VU University Medical Centre,
Groningen University Hospital, Amphia Hospital Breda, St
Franciscus Hospital Rotterdam or University Medical Centre,
Utrecht. The patients had not been in foreign hospitals within
the previous 2 months.
Microbiology
Nasal swabs were transported in Amies medium (Greiner bv,
Alphen aan den Rijn, The Netherlands). Swabs were inoculated
in 5 mLof Staphylococcal broth (DifcoLaboratories,Detroit,MI,
USA). After incubation for 48 h at 37C, the broths were
subculturedon to amannitol salt agarplate (Oxoid,Basingstoke,
UK) containingoxacillin 6 mg ⁄L (OMSA), andon toabloodagar
baseplate (Oxoid) containing tobramycin32 mg ⁄L (BAT). These
plateswere examined for growthafter incubation for 24 and48 h
at 37C. The plate with tobramycin was used to detect strains
with low-level oxacillin resistance that were also tobramycin-
resistant. It is the general experience in Dutch laboratories that
such strains do not grow well on the OMSA plate, but do grow
on theBATplate.S. aureuswas identifiedby catalaseproduction,
Staphaurex Plus rapid latex reagent (Murex, Dartford, UK) and
the tube coagulase test. All S. aureus isolates were checked for
penicillin-binding protein (PBP)-2a expression with the MRSA-
screen test (Bipharm, Weesp, The Netherlands). If the MRSA-
screen test was inconclusive, PCR for detection of themecA gene
was performed [10].
Throat swabswere inoculated on toMacConkeyagar (Oxoid)
for isolation of GGNB, and then placed in 5 mL of Staphylococ-
cal broth and processed further as described above.
Anal swabs were inoculated on to BAT and OMSA plates
and processed as described above. In addition, anal swabs
were inoculated on to MacConkey agar containing gentamicin
16 mg ⁄L, and then placed in 10 mL of enterococcal enrichment
broth (EB; Becton Dickinson, Sparks, MD, USA) containing
aztreonam 75 mg ⁄L. Plates were incubated for 48 h at 37C.
GGNB were identified with the Vitek automated system
(bioMe´rieux, Marcy l’Etoile, France). MICs of gentamicin were
determined by Etest (AB Biodisk, Solna, Sweden), with an MIC
‡ 8 mg ⁄L considered to represent resistance according to
National Committee for Clinical Laboratory Standards criteria
[11].
Enterococcal broths that turned black after incubation for
24 h were subcultured on to enterococcal agar (EA; Becton
Dickinson), without addition of antimicrobial agents, and
incubated for 48 h at 37C. Identification of enterococci was
done with the API-Rapid Strep system (bioMe´rieux). MICs of
vancomycin and amoxycillin were determined with Etests.
According to National Committee for Clinical Laboratory
Standards criteria [11], MICs of ‡ 32 mg ⁄L and ‡ 16 mg ⁄L were
considered to represent resistance to vancomycin and amoxy-
cillin, respectively.
Statistical analysis
The number of study participants escorted by the ANWB
repatriation organisation was compared with the total number
of escorted repatriations by this organisation during a 7-month
period in 1998–1999, to estimate the participation rate. For risk
factor analysis, clinical diagnoses were grouped into 17
categories according to the international classification of
diseases, 9th revision [12]. Groups of categories with the lowest
prevalence of the specific resistant microorganism were chosen
as reference groups. Antimicrobial agents were categorised
into six groups (Table 1). Because many patients were given
several antimicrobial agents, risk analysis of antimicrobial
treatment was performed according to the category of antimi-
crobial agents, and not according to the patient. The countries
from which the patients were repatriated were grouped into
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11 regions (Table 2). For risk analysis of the repatriation
countries, country areas with a known low prevalence of
MRSA carriage were chosen as the reference [13,14]. Statistical
analysis was performed with SPSS v.9 (SPSS Inc., Chicago, IL,
USA). Continuous variables were compared with Student’s
t-test for independent samples (two-tailed). Dichotomous
variables were compared with a two-tailed Fisher’s exact test
for 2 · 2 comparisons or Pearson’s chi-squared test for more
than two variables. Odds ratios (ORs) and corresponding 95%
confidence intervals (95% CIs) were calculated. The OR was
not calculated for groups which contained < 25 patients, as
these groups were considered too small for empowered
statistics. A logistic regression analysis was carried out with
forced inclusion of the following variables: length of stay in the
foreign hospital, antimicrobial treatment, and geographical
region. In the analysis of artificial ventilation as a risk factor,
intensive care stay was included in the model; in the analysis of
surgery as a risk factor, the presence of a urinary catheter was
included; and in the analysis of antimicrobial treatment as a
risk factor, surgery was included. Adjusted ORs with a p value
< 0.05 were considered to be significant.
RESULTS
From May 1998 until September 2001, 1167
patients were included in the study, of whom
58.9% were male. The participation rate was
26.5%. Comparison of the countries from which
participating patients were repatriated (Table 2)
showed no significant difference with those of
non-participants. The mean age of the repatriates
was 53.7 years (median 57 years), and the mean
length of stay in the foreign hospital was
13.1 days (median 10 days). In total, 202 (22.0%)
patients were repatriated from a university hos-
pital, 580 (49.7%) were admitted to a Dutch
hospital upon repatriation, and 587 (50.3%) were
repatriated directly to their homes. The preval-
ence of carriage of resistant microorganisms was
Table 1. Association of patient-related factors with carriage of resistant microorganisms for 1167 repatriated patients
Patient-related factor
Total
patientsa
No. (%)
with factor
No (%) of patients carrying Adjusted odds ratio (95% CI)
MRSA VRE GGNB MRSA VRE GGNB
Length of stay in
foreign hospital
‡ 14 days
1167 356 (30.5) 22 (6.2) 15 (4.2) 61 (17.1) 5.4b (2.3–12.0) 1.6 (0.7–3.6) 1.3 (0.8–1.9)
Underlying diseases
Treatment by
medical specialist
before travel
1138 583 (51.2) 18 (3.1) 16 (2.7) 94 (16.1) 1.1 (0.5–2.5) 1.2 (0.5–2.7) 1.6b (1.1–2.4)
Malignant disorder 1071 94 (8.8) 5 (5.3) 4 (4.3) 15 (16.0) 1.8 (0.6–5.7) 1.6 (0.5–5.1) 1.3 (0.7–2.4)
Heart disorder 1100 269 (24.5) 4 (1.5) 11 (4.1) 47 (17.5) 0.5 (0.2–1.5) 1.8 (0.8–3.9) 1.7b (1.1–2.7)
Lung disorder 1074 149 (13.9) 6 (4.0) 4 (2.7) 28 (18.8) 1.2 (0.5–3.3) 0.8 (0.3–2.5) 1.6 (1.0–2.7)
Diabetes mellitus 1070 86 (8.0) 2 (2.3) 4 (4.7) 16 (18.6) 0.6 (0.1–3.0) 1.8 (0.6–6.0) 1.3 (0.7–2.6)
Skin disorder 974 123 (12.6) 1 (0.8) 3 (2.4) 18 (14.6) 0.3 (0–2.2) 0.8 (0.2–3.0) 0.9 (0.4–1.7)
Acute diseases
Infectious disease 1156 90 (7.8) 3 (3.3) 5 (5.6) 16 (17.8) 12.9 (0.6–253.0) 0.4 (0.1–3.2) 4.2 (0.8–22)
Neoplasm 1156 37 (3.2) 2 (5.4) 0 2 (5.4) 22.7 (1.0–484.0) Reference
categoryc
Reference
category
Nervous system 1156 234 (20.2) 11 (4.7) 6 (2.6) 32 (13.7) 16.7 (0.9–284.0) 0.7 (0.1–3.4) 3.1 (1.0–9.2)
Circulatory system 1156 227 (19.6) 1 (0.4) 5 (2.2) 30 (13.2) 1.0 (0.9–1.0) 0.5 (0.1–3.0) 3.2b (1.1–9.6)
Respiratory system 1156 54 (4.7) 0 2 (3.7) 11 (20.4) Reference
category
1.1 (0.1–11.0) 3.3 (0.8–15.0)
Digestive system 1156 42 (3.6) 0 0 10 (23.8) Reference
category
Reference
category
33.2b (2.7–413.0)
Genitourinary system 1156 23 (2.0) 2 (8.7) 1 (4.3) 5 (21.7) NC NC NC
Musculoskeletal system 1156 26 (2.2) 0 0 3 (11.5) Reference
category
Reference
category
Reference
category
Injury 1156 384 (33.2) 11 (2.9) 9 (2.3) 51 (13.3) 9.9 (0.6–170.0) 0.8 (0.2–3.7) 2.9 (0.8–7.5)
Other 1156 50 (3.4) 0 3 (7.7) 4 (10.3) Reference
category
Reference
category
Reference
category
Wounds 1106 354 (32.0) 17 (4.8) 13 (3.7) 50 (14.1) 1.8 (0.8–4.1) 1.6 (0.7–3.7) 0.7 (0.5–1.2)
Treatment
Intensive care 1137 437 (38.4) 19 (4.3) 13 (3.0) 66 (15.1) 0.3 (0.1–1.3) 0.8 (0.3–2.0) 1.0 (0.6–1.5)
Artificial ventilation 1120 152 (13.6) 16 (10.5) 6 (3.9) 26 (17.1) 8.5b (1.8–41.0) 1.0 (0.3–3.8) 1.3 (0.7–2.6)
Surgery 1137 319 (28.1) 18 (5.6) 12 (3.8) 51 (16.0) 1.9 (0.8–4.6) 1.2 (0.5–2.9) 1.0 (0.6–1.6)
Urinary catheter 1117 393 (35.2) 23 (5.9) 12 (3.1) 69 (17.6) 2.4 (0.8–6.7) 0.6 (0.2–1.4) 1.1 (0.7–1.8)
Central venous catheter 1140 127 (11.1) 10 (7.9) 4 (3.1) 28 (22.0) 1.7 (0.7–4.1) 0.8 (0.3–2.6) 2.3 (1.4–4.0)
Antimicrobial treatment 1093 485 (44.4) 25 (5.2) 22 (4.5) 87 (17.9) 3.4b (1.2–9.7) 2.5b (1.2–5.8) 1.5 (1.0–2.3)
Aminoglycosides 45 (4.1) 6 (13.2) 0 10 (26.3) 11.6 (2.2–60.0) 0.6 (0–11.0) 2.4 (1.0–5.8)
Cephalosporins 111 (10.2) 8 (7.2) 3 (2.7) 22 (19.8) 5.3 (1.5–20.0) 2.5 (0.6–10.0) 1.6 (0.8–3.0)
Quinolones 51 (4.7) 5 (9.8) 1 (2.0) 14 (27.5) 7.6 (1.5–39.0) 1.4 (0.1–17.0) 2.7 (1.2–6.2)
Macrolides ⁄ lincosamides 32 (2.9) 1 (3.1) 4 (12.5) 4 (12.5) 3.7 (0.4–37.0) 16.7 (3.2–86.0) 0.6 (0.2–2.3)
Metronidazole 27 (2.5) 4 (14.8) 8 (29.6) 4 (14.8) 11.3 (2.0–63.0) 4.7 (0.8–29.0) 2.4 (0.9–7.0)
Penicillins 104 (9.5) 5 (4.8) 5 (4.8) 18 (17.3) 3.9 (0.9–17.0) 7.0 (1.7–29.0) 2.0 (1.0–3.9)
aNumber of patients from whom data on the specified item were available.
bSignificant adjusted odds ratios.
cCategories with low prevalence of the specific resistant microorganism.
CI, confidence interval; GGNB, gentamicin-resistant Gram-negative bacilli; MRSA, methicillin-resistant Staphylococcus aureus; NC, no calculation of the odds ratio because the
group contained < 25 patients; VRE, vancomycin-resistant enterococci.
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18.2% (95% CI 15.9–20.3). Nine patients carried
both MRSA and GGNB, two patients carried
MRSA and VRE, and five patients carried VRE
and GGNB. Antimicrobial treatment, length of
stay in the foreign hospital (mean 17.6 vs.
12.1 days; p < 0.001) and repatriation countries
(p < 0.001) were risk factors for carriage of resist-
ant microorganisms.
MRSA
Thirty-one patients (2.7%; 95% CI 1.7–3.6) carried
MRSA. Of patients repatriated to a Dutch hospi-
tal, 27 (4.7%; 95% CI 2.9–6.4) carried MRSA,
compared to only four (0.7%; 95% CI 0.02–1.3) of
the patients who were repatriated to their home.
Length of stay in a foreign hospital, artificial
Table 2. Association between country of repatriation and isolation of resistant microorganisms
Area: Countrya No. of patients
No. of patients carrying Adjusted odds ratios (95% CI)
MRSA VRE GGNB MRSA VRE GGNB
Referenceb 146 1 4 4 1.0 1.0 1.0
Germany 90 0 2 4 NC NC NC
Switzerland 34 1 1 0 NC NC NC
Iceland 1 0 1 0 NC NC NC
Middle/West Europe 147 8 5 5 6.7 (0.7–61.0) 1.0 (0.2–4.4) 1.0 (0.1–6.9)
Austria 86 2 2 2 3.0 (0.3–36.0) 0.9 (0.1–4.9) 0.6 (0.1–8.5)
Belgium 31 3 0 3 9.0 (0.8–109.0) 0.5 (0–9.5) 3.7 (0.4–33.0)
UK 21 3 3 0 NC NC NC
Southern Europe 543 13 5 62 2.7 (0.3–21.0) 0.3 (0.1–1.1) 7.4 (1.8–31.0)
Spain 233 3 4 40 0.8 (0.1–9.9) 0.4 (0.1–2.1) 11.8c (2.7–50.0)
France 207 4 1 12 2.9 (0.3–26.0) 0.2 (0–1.5) 3.7 (0.8–17.0)
Italy 63 3 0 9 6.0 (0.6–62.0) 0.2 (0–4.7) 10.3 (2.1–52.0)
Portugal 34 3 0 1 10 (0.8–117.0) 0.5 (0–8.7) 3.0 (0.3–36.0)
Southeastern Europe 100 3 4 30 3.1 (0.3–31.0) 1.1 (0.3–4.6) 25.0c (5.2–108.0)
Turkey 52 0 1 21 0.9 (0–23.0) 0.5 (0.1–4.9) 36.7c (8.0–167.0)
Greece 45 3 3 8 6.4 (0.6–65.0) 1.9 (0.4–9.1) 13.0c (2.6–66.0)
Cyprus 3 0 0 1 NC NC NC
Asia 56 4 7 25 5.9 (0.5–69.0) 5.6c (1.5–21.0) 82.7c (16.0–424.0)
Thailand 15 1 1 8 NC NC NC
Indonesia 13 1 5 3 NC NC NC
China 9 1 0 3 NC NC NC
India 5 0 0 3 NC NC NC
Malaysia 5 0 1 4 NC NC NC
Singapore 5 1 0 3 NC NC NC
Sri Lanka 2 0 0 1 NC NC NC
Vietnam 1 0 0 1 NC NC NC
Eastern Europe 29 0 4 10 1.2 (0–31.0) 3.3 (0.7–15.0) 29.4c (5.8–147.0)
Czech Republic 8 0 1 2 NC NC NC
Hungary 6 0 1 0 NC NC NC
Croatia 5 0 0 1 NC NC NC
Romania 3 0 0 3 NC NC NC
Lithuania 2 0 0 2 NC NC NC
Poland 2 0 0 2 NC NC NC
Bulgaria 1 0 1 0 NC NC NC
South and Central America 19 0 0 8 NC NC NC
Dutch Antilles 7 0 0 2 NC NC NC
Venezuela 6 0 0 2 NC NC NC
Surinam 5 0 0 3 NC NC NC
Uruguay 1 0 0 1 NC NC NC
North America 33 0 3 3 NC NC NC
USA 16 0 3 0 NC NC NC
Canada 15 0 0 1 NC NC NC
Mexico 2 0 0 2 NC NC NC
Africa 24 1 0 6 NC NC NC
Morocco 6 0 0 3 NC NC NC
Tunisia 5 0 0 1 NC NC NC
South Africa 5 1 0 0 NC NC NC
Senegal 2 0 0 1 NC NC NC
Uganda 1 0 0 1 NC NC NC
Middle East 14 1 1 7 NC NC NC
Israel 9 0 1 3 NC NC NC
Egypt 3 1 0 3 NC NC NC
Iran 1 0 0 1 NC NC NC
Australia 12 0 0 1 NC NC NC
Unknown 34 0 0 3 NC NC NC
aUnlisted countries with no resistant microorganisms: reference group—Norway (14), Finland (4), Denmark (2), Sweden (1); middle/west Europe—Luxembourg (6), Ireland
(3); southern Europe—Malta (6); Asia—Nepal (1); eastern Europe—Slovakia (1), Slovenia (1); Central and South America—Brazil (2), Chile (2), Bolivia (1), Peru (1), Ecuador (1),
Cuba (1), Guatemala (1), Jamaica (1); Africa—Zimbabwe (2), Kenya (1), Namibia (1), Zambia (1); Middle East—Arab Emirates (1).
bCountries with a low prevalence of the specific resistant microorganism.
cSignificant adjusted odds ratios.
MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci; GGNB, gentamicin-resistant Gram-negative bacilli; NC, no calculation of the odds
ratio because group contains < 25 patients.
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ventilation and antimicrobial treatment were risk
factors for MRSA carriage (Table 1).
VRE
Thirty-two patients (2.7%; 95% CI 1.8–3.7) carried
VRE. Of the 32 isolates of VRE, 26 (78.8%) were
Enterococcus faecium, five (15.2%) were Enterococ-
cus faecalis, and one was an unspeciated entero-
coccus. Half of the patients carrying VRE were
repatriated to a Dutch hospital. Ten (38.5%) of the
26 E. faecium isolates, but none of the E. faecalis
isolates, were resistant to both vancomycin and
amoxycillin. Antimicrobial treatment (Table 1)
and repatriation from Asia (Table 2) were risk
factors for VRE carriage.
GGNB
In total, 164 (14.1%; 95% CI 12.1–16.0) patients
carried GGNB, including 74 (6.3%) colonised
with gentamicin-resistant Escherichia coli, 30
(2.6%) with Acinetobacter spp., 15 (1.3%) with
Klebsiella pneumoniae, 13 (1.1%) with Pseudomonas
aeruginosa, and 58 with other GGNB. Seventy-five
(46.3%) of the patients carrying GGNB were
repatriated to a Dutch hospital. A medical history
(i.e., involving treatment by a medical specialist)
before travel and underlying heart disorders were
independent risk factors for carriage of GGNB
(Table 1). Acute diseases of the circulatory system
and the digestive system also seemed to be linked
with an increased risk for carriage of GGNB. The
risk for acquisition of GGNB was highest in Asia,
with c. 45% of all repatriates from this region
carrying GGNB, followed by repatriates from
eastern and southern Europe (Table 2). Within
Asia, four of five patients from Malaysia, three of
five patients from India, three of five patients
from Singapore and eight of 15 patients from
Thailand carried GGNB. Among the 200 patients
included in the prevalence study undertaken to
provide reference data on carriage of GGNB in
Dutch hospitals, nine (4.5%) patients were found
with GGNB (five Escherichia coli, two Enterobacter
spp. and two Klebsiella spp.).
DISCUSSION
Nearly one in five patients repatriated from a
foreign hospital to The Netherlands carried at
least one resistant microorganism upon repatri-
ation. This is a very high rate compared with the
prevalence of carriage of MRSA, VRE and GGNB
among patients staying in Dutch hospitals. Previ-
ous studies have shown that the prevalence rate
of MRSA carriage in The Netherlands is < 1%
[2,4], while that of the carriage of VRE is 2%
[1,15]. In the present study, it was found that the
prevalence of carriage of GGNB in a sample of
patients drawn from five different Dutch hospi-
tals was 4.5%.
Only a few patients were repatriated from
many countries, so countries were grouped into
11 geographical regions for the purposes of
analysis. The countries with the lowest carriage
rates of resistant microorganisms were designated
as the reference group, and included the Scandi-
navian countries, Germany and Switzerland. Car-
riage rates of all three resistant microorganisms in
this reference group were < 3%. Other authors
have also reported a low prevalence of carriage of
MRSA [13,14,16], GGNB [17,18] and VRE [19] in
these countries.
A weakness of the present study was the low
participation rate (26.5%). There were many
reasons for this, including refusal to participate
by the patient, non-compliance of the escorting
personnel, health status of the patients precluding
informed consent and ⁄ or swab specimen collec-
tion, and the loss of culture specimens. The study
also depended on Dutch travel habits, so most of
the data related to typical Dutch holiday destina-
tions such as Spain and Turkey.
The design of the study ensured that all culture
specimens were obtained immediately after the
patient had left the foreign hospital, during the
repatriation journey, and that all cultures and
antimicrobial susceptibility tests were performed
in the same laboratory.
The overall carriage rate of MRSA in repatriates
from foreign hospitals was 2.7%. This is low
compared with the rates in many countries, but is
high compared with the average carriage rate of
MRSA in Dutch hospitals. However, the MRSA
carriage rate among repatriates who were suffi-
ciently ill to require admittance to a hospital upon
arrival in The Netherlands was almost 5%.
Within the group of repatriates who were read-
mitted to a Dutch hospital, the rate of MRSA
carriage was about the same as that reported by
Kruithof and Ta¨rre in 1993 [20]. Length of stay in
a foreign hospital, artificial ventilation and anti-
microbial treatment were independent risk factors
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for MRSA carriage. Other investigators have
reported similar risk factors for MRSA carriage
[21,22]. The association of such risk factors sug-
gests that MRSA carriage is more common among
severely ill patients [22,23]. However, four
patients repatriated to their homes were also
found to be MRSA carriers. According to Dutch
policies, only patients who are repatriated di-
rectly from a foreign hospital to a Dutch hospital
are automatically screened for MRSA carriage.
Therefore, patients who are repatriated to their
homes could function as unrecognised sources of
MRSA; their possible role in the epidemiology of
MRSA in The Netherlands may have to be
monitored in the future.
A Dutch national surveillance study showed
that the proportion of patients whose acquisition
of MRSA could be traced to admission to a foreign
hospital decreased from 45% in 1995 to 10% in
2003, while the total prevalence of MRSA carriage
in The Netherlands slightly increased to 0.5%
in 2002 [9,24]. A long-term surveillance study
among repatriated patients in our own hospital
showed that MRSA carriage rates declined from
8% in 1993–1996 to 2% in 1999–2001 [25]. This
indicates that increasing numbers of Dutch MRSA
isolates are either circulating autochthonous
strains, or are strains introduced by patients
who were repatriated to their homes. The rela-
tionship between country of origin and MRSA
carriage was not significant (Table 2), although
high prevalence rates for MRSA carriage were
found among patients repatriated from the UK
(14%), Belgium (10%) and Portugal (9%). The
high MRSA carriage rates in repatriates from
these countries mirror the known high MRSA
prevalence [26–28], and the absence of statistical
significance for country as a risk factor in the
present study might result from the low numbers
of carriers.
The prevalence of carriage of VRE among
repatriates (2.7%) was about the same as in the
Dutch community. A survey performed in 1995
on stool samples from 624 inpatients and 200
outpatients showed a 2% prevalence of colonisa-
tion with VRE for both groups [1]. From this
perspective, travel to foreign countries did not
seem to pose a risk for acquisition of VRE.
However, when subgroups of patients were ana-
lysed, e.g., those receiving antimicrobial treat-
ment or those repatriated from Asia, differences
in the carriage of VRE were observed. There may
be a difference between the type of VRE acquired
in foreign hospitals and those acquired in the
community in The Netherlands. Such differences,
e.g., the presence of the esp gene, have already
been shown to exist between strains that cause
outbreaks in hospitals and community-acquired
strains [29]. The present study did not determine
whether the esp gene was more prevalent among
strains of VRE acquired abroad, but it was noted
that about one-third of isolates were resistant to
both vancomycin and amoxycillin, which may
indicate hospital rather than community acquisi-
tion.
Increasing numbers of studies have shown high
levels of aminoglycoside resistance among Gram-
negative bacteria causing outbreaks in hospitals
[5,17]. The present study focused on gentamicin
resistance because this is the aminoglycoside
prescribed most commonly in The Netherlands.
Unfortunately, the relatively small numbers of
carriers of each individual species precluded a
risk analysis at the species level. Nevertheless,
almost one in six repatriated patients carried
GGNB, which is higher than the figure for GGNB
of 2–13.1% found in the SENTRY European
Surveillance programme in 1999 [5]. Surveillance
data from eight Dutch laboratories indicated that
gentamicin resistance in Gram-negative bacilli
from clinical samples is < 1% [3]. The results
from the small study performed in Dutch hospi-
tals to obtain current prevalence data on GGNB
showed that the prevalence (4.5%) was one-third
of that found in repatriates. The country from
which patients were repatriated was strongly
associated with carriage of GGNB (Table 2). With
almost half of the repatriates from Asia carrying
GGNB, this was clearly a risk region for GGNB.
Three of five repatriates from Singapore carried
GGNB, and Chiew et al. [30] reported a 22%
prevalence rate for carriage of GGNB in a Singa-
pore hospital in 1993. Repatriates from Turkey
had a prevalence rate for carriage of GGNB of
40%, and previous studies have indicated that
Turkey has prevalence rates for GGNB as high as
80% [17,31,32]. Almost 12% of repatriates from
southern Europe carried GGNB, which is in
accordance with the results of two European
surveillance studies of carriage of GGNB in
southern Europe [5,17].
The results of this study may have implications
for Dutch infection control policy. Dutch guide-
lines for MRSA have proven effective to date, and
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the data from the present study underscore the
validity of screening patients who come from
foreign hospitals to avoid introduction of MRSA
from abroad. For VRE, there does not seem to be a
need for action. However, the results for GGNB
raise the question of whether an isolation and
screening policy should be implemented for
Gram-negative bacilli. A first step towards such
a policy was made in 2003 by the Dutch Working
Party for the Prevention of Infection, which issued
for discussion a preliminary guideline concerning
control measures for resistant Gram-negative
bacteria.
It is assumed that the use of antimicrobial
drugs is the main cause of selection for resistant
strains, generally referred to as antimicrobial
pressure [33]. A remarkable finding in the
present study was the lack of a relationship
between the use of antimicrobial drugs at the
individual patient level and the carriage of
resistant strains. However, the association
between certain countries and resistance clearly
reflected known patterns of high antimicrobial
drug use. It was concluded that antimicrobial
treatment given to an individual patient may not
be the major risk factor for colonisation with
resistant microorganisms, but that this risk may
be determined mainly by the overall prevalence
of resistant strains in the hospital, which in itself
is the result of antimicrobial use in general and
the overall standard of infection control prac-
tices.
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